a bit of history alzheimer's disease – named after alois

20
A bit of history A bit of history Alzheimer’s disease – named after Alzheimer’s disease – named after Alois Alzheimer who first Alois Alzheimer who first described it back in 1906 described it back in 1906 Now dementia affects 24 million Now dementia affects 24 million people world-wide, 60% in people world-wide, 60% in developing countries. developing countries. 0.5 million people in UK. 0.5 million people in UK. Comes third in disability indices. Comes third in disability indices.

Upload: cardiacinfo

Post on 09-Jun-2015

1.309 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: A bit of history Alzheimer's disease – named after Alois

A bit of historyA bit of history

Alzheimer’s disease – named after Alzheimer’s disease – named after Alois Alzheimer who first described it Alois Alzheimer who first described it back in 1906back in 1906

Now dementia affects 24 million Now dementia affects 24 million people world-wide, 60% in developing people world-wide, 60% in developing countries.countries.

0.5 million people in UK.0.5 million people in UK. Comes third in disability indices.Comes third in disability indices.

Page 2: A bit of history Alzheimer's disease – named after Alois

DementiaDementia

Loss of intellectual functions Loss of intellectual functions including memory.including memory.

Deterioration in ability to carry out Deterioration in ability to carry out day to day activities.day to day activities.

Changes in social behaviour.Changes in social behaviour.

Page 3: A bit of history Alzheimer's disease – named after Alois

Alzheimers dementiaAlzheimers dementia

Most common form.Most common form. Behaviour changes often take form of Behaviour changes often take form of

apathy and social withdrawal but also apathy and social withdrawal but also behavioural disturbance.behavioural disturbance.

Leads to death of selected nerve cells Leads to death of selected nerve cells in the CNS.in the CNS.

Average survival post diagnosis 8-10 Average survival post diagnosis 8-10 years.years.

Page 4: A bit of history Alzheimer's disease – named after Alois

Vascular dementiaVascular dementia

Role of vascular events in aetiology Role of vascular events in aetiology of dementia poorly understood.of dementia poorly understood.

Onset may be abrupt or may be Onset may be abrupt or may be stepwise progression.stepwise progression.

Physical problems are more common Physical problems are more common than in AD.than in AD.

Page 5: A bit of history Alzheimer's disease – named after Alois

Lewy body dementiaLewy body dementia

Fluctuation of awareness from day to Fluctuation of awareness from day to day.day.

Signs of ParkinsonismSigns of Parkinsonism Visual hallucinations or delusions.Visual hallucinations or delusions. Similar to dementia seen in patients Similar to dementia seen in patients

with Parkinson’s disease (affects 75% with Parkinson’s disease (affects 75% after 10 years).after 10 years).

Page 6: A bit of history Alzheimer's disease – named after Alois

The othersThe others

Fronto-temporal dementia.Fronto-temporal dementia. CJD.CJD. Mixed dementia.Mixed dementia.

Page 7: A bit of history Alzheimer's disease – named after Alois

DiagnosisDiagnosis

HistoryHistory Ideally using diagnostic criteria eg. DSM4Ideally using diagnostic criteria eg. DSM4

Cognitive testingCognitive testing MMSEMMSE

Screening for reversible causesScreening for reversible causes Only if clinically indicatedOnly if clinically indicated Assess for depressionAssess for depression

ImagingImaging CT +/- SPECTCT +/- SPECT

Page 8: A bit of history Alzheimer's disease – named after Alois

Non-pharmacological Non-pharmacological interventionsinterventions

Supporting care giversSupporting care givers Cognitive stimulationCognitive stimulation Environment designEnvironment design Physical activitiesPhysical activities Recreational activitiesRecreational activities

Page 9: A bit of history Alzheimer's disease – named after Alois

Cholinesterase inhibitorsCholinesterase inhibitors

Inhibit the enzymatic breakdown of Inhibit the enzymatic breakdown of acetylcholine.acetylcholine.

Efficacy on reducing cognitive decline Efficacy on reducing cognitive decline of three main drugs the same.of three main drugs the same.

Donepezil possibly better tolerated.Donepezil possibly better tolerated. Long term use may delay Long term use may delay

institutionalisation.institutionalisation.

Page 10: A bit of history Alzheimer's disease – named after Alois

DonepezilDonepezil

Can be used to treat cognitive decline Can be used to treat cognitive decline in mild-mod AD and vascular dementia.in mild-mod AD and vascular dementia.

Reduces psychotic symptoms and some Reduces psychotic symptoms and some behavioural problems in mild-mod AD.behavioural problems in mild-mod AD.

Treatment daily doses of 5mg or above.Treatment daily doses of 5mg or above.

Page 11: A bit of history Alzheimer's disease – named after Alois

GalantamineGalantamine

Can be used for treatment of cognitive Can be used for treatment of cognitive decline in AD and mixed dementias.decline in AD and mixed dementias.

Can be used for Mx of associated Can be used for Mx of associated symptoms including functional ability symptoms including functional ability in AD.in AD.

Higher doses up to 24mg/day more Higher doses up to 24mg/day more effective; slow dose escalation effective; slow dose escalation improves tolerability.improves tolerability.

Page 12: A bit of history Alzheimer's disease – named after Alois

RivastigmineRivastigmine

Shown to reduce cognitive decline Shown to reduce cognitive decline and improve associated symptoms in and improve associated symptoms in patients with AD and Lewy body patients with AD and Lewy body dementia.dementia.

Page 13: A bit of history Alzheimer's disease – named after Alois

MemantineMemantine

NMDA receptor antagonist.NMDA receptor antagonist. Small benefits in wide range of Small benefits in wide range of

measures and activities of daily living measures and activities of daily living in patients with mild-mod AD and in patients with mild-mod AD and vascular dementia but not vascular dementia but not statistically significant.statistically significant.

Insufficient evidence to back up its Insufficient evidence to back up its use.use.

Page 14: A bit of history Alzheimer's disease – named after Alois

Ginkgo BilobaGinkgo Biloba

Studies looked at use in dementiasStudies looked at use in dementias Has a positive effect on cognition and Has a positive effect on cognition and

function but less than cholinesterase inhib.function but less than cholinesterase inhib. Benefit most pronounced in advanced AD.Benefit most pronounced in advanced AD. Safe though interacts with medicines e.g. Safe though interacts with medicines e.g.

increased clotting time on warfarin.increased clotting time on warfarin. Needs to be used for 1 year to see Needs to be used for 1 year to see

improvements.improvements.

Page 15: A bit of history Alzheimer's disease – named after Alois

Use of AntipsychoticsUse of Antipsychotics

Are effective for treatment of Are effective for treatment of behavioural problems.behavioural problems.

Older and atypical forms have similar Older and atypical forms have similar efficacy.efficacy.

Risk of stroke with atypical Risk of stroke with atypical antipsychotics.antipsychotics.

Significant SE profile – needs monitored.Significant SE profile – needs monitored. No causal link to accelerated No causal link to accelerated

progression of dementia.progression of dementia.

Page 16: A bit of history Alzheimer's disease – named after Alois

Things that don’t workThings that don’t work

Anti-inflammatoriesAnti-inflammatories HydroxychloroquineHydroxychloroquine PrednisolonePrednisolone MelatoninMelatonin OestrogensOestrogens SelegilineSelegiline

Page 17: A bit of history Alzheimer's disease – named after Alois

The cholinesterase inhibitors The cholinesterase inhibitors debatedebate

Use limited by NICE to moderate dementia Use limited by NICE to moderate dementia (MMSE 10-20). (MMSE 10-20).

Yearly cost of £1000/pt.Yearly cost of £1000/pt. 1/3 of patients stop after 3mths due to SE.1/3 of patients stop after 3mths due to SE. Challenged in courts on basis that Challenged in courts on basis that

economic model not released for scrutiny.economic model not released for scrutiny. Are rigid cut-offs in MMSE a fair way to Are rigid cut-offs in MMSE a fair way to

assess eligibility for treatment?assess eligibility for treatment?

Page 18: A bit of history Alzheimer's disease – named after Alois

The cholinesterase inhibitors The cholinesterase inhibitors debatedebate

Less than 20% of patients with Less than 20% of patients with dementia treated with these meds.dementia treated with these meds.

Cost 30% more in UK than Europe.Cost 30% more in UK than Europe. Poor standard of care compared to Poor standard of care compared to

other countriesother countries 1/3 of patients receive a formal 1/3 of patients receive a formal

diagnosisdiagnosis Use of cholinesterase inhibitors less Use of cholinesterase inhibitors less

widespread.widespread.

Page 19: A bit of history Alzheimer's disease – named after Alois

Current NICE guidelinesCurrent NICE guidelines

Donepezil, Galantamine and Donepezil, Galantamine and Rivastigmine used in mild-mod Rivastigmine used in mild-mod severe ADsevere AD MMSE 10-20MMSE 10-20 Initiated by specialistInitiated by specialist R/V every 6/12R/V every 6/12 Only continued if MMSE >= 10 and Only continued if MMSE >= 10 and

clinically worthwhile.clinically worthwhile.

Page 20: A bit of history Alzheimer's disease – named after Alois

Current NICE guidelinesCurrent NICE guidelines

Memantine not recommended Memantine not recommended Patients already on Tx can continue Patients already on Tx can continue

until considered appropriate to stop.until considered appropriate to stop.